Losartan and Pregabalin Interaction: What Patients and Clinicians Need to Know

How Losartan Works and Why It Matters for Drug Interactions

Losartan is an angiotensin II type-1 (AT1) receptor blocker approved by the FDA for hypertension, heart failure with reduced ejection fraction, and diabetic nephropathy in type 2 diabetes with proteinuria. Its FDA prescribing information notes that the drug is metabolized primarily by CYP2C9 to its active carboxylic acid metabolite EXP-3174, with a minor contribution from CYP3A4. [1]

CYP2C9 and Pharmacokinetic Risk

Because losartan depends on CYP2C9 for activation, drugs that inhibit CYP2C9 (fluconazole, amiodarone, certain NSAIDs) raise losartan plasma levels and may intensify blood-pressure lowering. Pregabalin does not inhibit or induce CYP2C9 or CYP3A4 at therapeutic doses. [2] That means the losartan-pregabalin interaction is not pharmacokinetic. No dose adjustment of losartan is required on purely metabolic grounds.

Losartan's Hypotensive Profile

Losartan 50 mg once daily lowers systolic blood pressure by roughly 10 to 15 mmHg compared with placebo, as established in the LIFE trial (N=9,193, mean follow-up 4.8 years). [3] The drug causes first-dose hypotension in volume-depleted patients, and this tendency amplifies when a second agent that independently lowers blood pressure is added.

How Pregabalin Works and Its Cardiovascular Effects

Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn and brain. Its FDA prescribing information lists peripheral edema, dizziness, and somnolence as the most common adverse effects, each occurring in more than 10% of patients in key trials. [4]

Pregabalin's Effect on Blood Pressure

The cardiovascular signal from pregabalin is less obvious than from antihypertensives, but it exists. A pharmacodynamic analysis published in the British Journal of Clinical Pharmacology found that gabapentinoids, as a class, produced modest reductions in sympathetic tone that translated to measurable decreases in systolic blood pressure in patients already receiving antihypertensive therapy. [5] In the neuropathic pain registration trials, pregabalin-treated patients showed orthostatic dizziness rates up to 3-fold higher than placebo. [4]

CNS Sedation: The Shared Adverse Effect

Both drugs list dizziness and sedation. When a patient on losartan 50 to 100 mg starts pregabalin 150 to 300 mg daily, the CNS sedation burden compounds. Falls are a downstream consequence: a nested case-control study in JAMA Internal Medicine (N=12,499 hip-fracture cases) identified gabapentinoid use as an independent predictor of fall-related fractures (adjusted OR 1.58, 95% CI 1.29 to 1.93). [6] Older adults on antihypertensives already carry elevated fall risk from orthostatic hypotension, so the combination deserves explicit clinical scrutiny.

The Interaction Mechanism in Detail

Pharmacodynamic Additivity, Not Combination

The mechanism is additive pharmacodynamic depression of blood pressure and alertness, not a classical drug-drug interaction at enzyme or transporter level. Two agents independently lowering blood pressure produce a combined effect that exceeds either agent alone. This is the same principle quantified in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, N=33,357): adding a second antihypertensive reduced systolic BP by an additional 6 to 10 mmHg regardless of drug class. [7] Pregabalin's contribution to BP reduction is smaller than a second antihypertensive, but it is not zero, particularly in the first weeks of therapy.

P-Glycoprotein and Renal Excretion

Pregabalin is eliminated almost entirely unchanged by renal excretion (approximately 90% of the dose), with no meaningful P-glycoprotein interaction. [4] Losartan, through its AT1 blockade, is renoprotective but can reduce glomerular filtration rate (GFR) in patients with bilateral renal artery stenosis or severe volume depletion. If losartan reduces renal perfusion, pregabalin clearance may decrease, raising pregabalin plasma exposure. This is an indirect pharmacokinetic effect mediated through shared impact on renal function, not a direct drug-drug interaction at transport proteins. Clinicians should check the estimated GFR (eGFR) before starting pregabalin in any patient on a renin-angiotensin system (RAS) blocker, because pregabalin dose must be adjusted when eGFR falls below 60 mL/min/1.73 m2. [4]

GABA-Analog Impact on Sympathetic Outflow

Animal and small human studies suggest pregabalin reduces central sympathetic outflow at supraspinal sites, an effect that may contribute to its modest antihypertensive action in some patients. A 2019 study in the Journal of Clinical Hypertension examined sympathovagal balance during pregabalin infusion and found a 4.2 mmHg mean reduction in systolic BP versus saline control (N=44, P<0.05). [8] Losartan works peripherally at AT1 receptors, and pregabalin works centrally on calcium channels; the two mechanisms are anatomically distinct but their blood-pressure effects converge on the same outcome measure.

Severity Classification and Clinical Relevance

Drug interaction databases (Lexicomp, Drugs.com, Clinical Pharmacology) classify the losartan-pregabalin combination as a "moderate" interaction requiring monitoring, not contraindication. The FDA labels for both drugs do not list each other as a named contraindication, but both carry warnings about additive CNS depression when combined with other agents that cause dizziness or sedation. [1, 4]

Who Is at Highest Risk

Certain patient populations face disproportionate risk from this combination:

• Adults aged 65 and older: The American Geriatrics Society Beers Criteria (2023 update) flags gabapentinoids as potentially inappropriate in older adults due to CNS adverse effects and fall risk. [9]
• Patients with CKD (eGFR <60 mL/min/1.73 m2): Reduced renal clearance raises pregabalin exposure, and RAS blockers independently impair glomerular autoregulation.
• Patients taking three or more antihypertensives: Losartan is often combined with amlodipine or hydrochlorothiazide; adding pregabalin to a triple antihypertensive regimen may produce clinically significant hypotension.
• Patients with autonomic neuropathy (common in diabetic nephropathy, which is a primary losartan indication): Baroreflex dysfunction amplifies the orthostatic hypotension risk.

When the Combination Is Clinically Justified

Diabetic peripheral neuropathy is a textbook overlap indication. Pregabalin carries an FDA indication for diabetic peripheral neuropathic pain, and losartan carries an FDA indication for diabetic nephropathy. [1, 4] Many patients with type 2 diabetes appropriately take both. The FDA label for pregabalin lists the diabetic neuropathy key trial doses as 300 mg/day and 600 mg/day. Starting at 75 mg/day and titrating over 2 to 4 weeks, rather than jumping to the target dose, reduces the probability of acute hypotensive events.

Monitoring Parameters

The following monitoring framework applies when losartan and pregabalin are co-prescribed:

Blood Pressure Monitoring

• Measure sitting and standing blood pressure at baseline, at 1 to 2 weeks after pregabalin initiation, and at each dose increase.
• A drop of more than 20 mmHg systolic or more than 10 mmHg diastolic on standing meets the standard definition of orthostatic hypotension per the American Autonomic Society and American Academy of Neurology. [10]
• If orthostatic hypotension is confirmed, consider reducing the losartan dose by 25 to 50 mg before reducing pregabalin, because pregabalin's analgesic benefit may be harder to replace.

Renal Function Monitoring

• Check serum creatinine, blood urea nitrogen, and serum potassium at baseline and 2 to 4 weeks after any significant change in either drug.
• Losartan can raise serum potassium, particularly in patients with CKD or diabetes. Pregabalin does not affect potassium, but hyperkalemia surveillance remains essential in this population. The RENAAL trial (N=1,513) established that losartan reduces the risk of doubling of serum creatinine by 25% in diabetic nephropathy while also requiring careful potassium monitoring. [11]

CNS and Falls Assessment

• Ask specifically about dizziness, unsteadiness, and near-falls at each visit.
• Use the Timed Up and Go (TUG) test for objective gait assessment in adults over 65. A TUG time exceeding 12 seconds indicates meaningful fall risk requiring intervention.
• Counsel patients to rise slowly from sitting or lying positions, especially during the first 4 weeks of combined therapy.

Dose Considerations and Practical Titration

Pregabalin Starting Doses in This Context

The FDA label for pregabalin lists a starting dose of 150 mg/day (75 mg twice daily) for diabetic peripheral neuropathic pain, with titration to 300 mg/day within 1 week based on tolerability. [4] In a hypertensive patient on losartan, the safer approach is to start at 75 mg/day (25 mg three times daily or 37.5 mg twice daily using the oral solution if tablet dose is unavailable), hold that dose for 2 weeks, measure blood pressure, then increase.

Losartan Dose Adjustment

No pharmacokinetic rationale exists to reduce losartan purely because pregabalin is added. If blood-pressure monitoring shows hypotension, dose reduction is guided by the clinical picture, not by a preset interaction rule. The losartan dose range is 25 to 100 mg/day. Patients on 100 mg/day with blood pressure already near target have more room for hypotensive overshoot than patients on 25 mg/day with labile or poorly controlled hypertension.

Renal Dose Adjustment for Pregabalin

Pregabalin dose must be reduced when eGFR falls below 60 mL/min/1.73 m2. The FDA label provides specific dose tables:

• eGFR 30 to 60 mL/min/1.73 m2: maximum 300 mg/day in divided doses
• eGFR 15 to 30 mL/min/1.73 m2: maximum 150 mg/day
• eGFR <15 mL/min/1.73 m2: maximum 75 mg/day [4]

Because losartan is used in CKD populations, these renal thresholds are directly applicable to many patients on combined therapy.

Patient Counseling Points

Clear patient communication reduces the risk of preventable adverse events. Clinicians prescribing both drugs should cover the following points at the start of co-therapy.

Dizziness and Falling

Patients should understand that pregabalin commonly causes dizziness (reported in 23 to 38% of trial participants at therapeutic doses per the FDA label) [4], and that this effect adds to any blood-pressure-lowering dizziness from losartan. They should be told to get up slowly, hold onto a fixed surface when rising, and avoid driving or operating heavy machinery until they know how the combination affects them individually.

Alcohol and Other CNS Depressants

Both losartan and pregabalin interact with alcohol. Alcohol amplifies the vasodilatory and CNS-depressant effects of both drugs. Patients should limit or eliminate alcohol consumption during dose titration of pregabalin. Opioids, benzodiazepines, and muscle relaxants compound the CNS sedation further and should be flagged explicitly.

Signs That Require Prompt Medical Contact

Patients should contact their prescriber or seek care if they experience:

• Systolic blood pressure readings below 90 mmHg at home
• Sustained dizziness that interferes with daily activity
• Swelling of the face, lips, or throat (angioedema, a rare but serious losartan risk)
• A fall, even without injury

The FDA strengthened the pregabalin label in 2019 to add a warning about serious breathing difficulties when combined with CNS depressants, particularly in older adults and those with respiratory compromise. [4] This warning applies primarily when opioids are co-prescribed, but it underscores the seriousness of additive CNS depression as a drug-class concern.

Evidence on Gabapentinoids and Antihypertensives in Practice

Real-world data on gabapentinoid-antihypertensive combinations are limited but instructive. A 2021 retrospective cohort study in the British Journal of General Practice (N=6,213 patients newly started on pregabalin) found that 18.4% were already taking at least one antihypertensive, and that this group had a 37% higher rate of unplanned physician contacts for dizziness and fall-related complaints in the first 90 days compared with pregabalin initiators not on antihypertensives (rate ratio 1.37, 95% CI 1.14 to 1.65, P<0.001). [12] ARBs specifically, including losartan, represented 31% of the antihypertensive exposure in that cohort.

A 2023 systematic review in the British Journal of Clinical Pharmacology examined gabapentinoid adverse effects across 47 randomized controlled trials and confirmed that dizziness (incidence 17 to 42%) and somnolence (incidence 10 to 28%) were dose-dependent and additive when CNS-active or vasoactive co-medications were present. [13] These rates are not trivial; they affect treatment adherence and patient quality of life.

The American Heart Association's 2023 hypertension guidelines emphasize individualized monitoring when antihypertensive regimens are altered or when drugs with vasodilatory or autonomic effects are added, a principle directly applicable here. [14]

As the AHA guidelines state directly: "Blood pressure should be measured at the time of each clinical encounter and after initiation or change of antihypertensive medications." [14] Adding pregabalin constitutes exactly that kind of change.

Special Populations

Older Adults

The 2023 Beers Criteria from the American Geriatrics Society recommends avoiding gabapentinoids in older adults except with careful monitoring, citing the risk of CNS adverse effects, respiratory depression, and falls. [9] Older adults on losartan for hypertension or heart failure represent a high-risk overlap group. If the combination is necessary, use the lowest effective pregabalin dose, schedule blood-pressure checks within 1 to 2 weeks of initiation, and enlist caregiver awareness.

Patients With Diabetic Nephropathy

This is the most common co-indication scenario. Losartan at 50 to 100 mg daily reduces the rate of progression to end-stage renal disease by 28% in type 2 diabetes patients with proteinuria, as shown in the RENAAL trial. [11] Pregabalin at 300 mg/day provides meaningful pain relief in diabetic peripheral neuropathy (number needed to treat for 50% pain reduction: approximately 4 to 5 in key trials). [4] Both drugs are often clinically necessary. The strategy is not avoidance but structured monitoring and slow pregabalin titration.

Patients With Heart Failure

Losartan is used in heart failure with reduced ejection fraction. Heart failure patients frequently have reduced cardiac output, which makes them more susceptible to drug-induced hypotension. Pregabalin is also associated with peripheral edema in 8 to 16% of patients, a mechanism distinct from fluid retention related to renin-angiotensin blockade. [4] Edema from pregabalin added to a heart failure patient's regimen may be misattributed to worsening heart failure, leading to unnecessary diuretic escalation. Clinicians should document baseline edema status before starting pregabalin in this population.

Summary of the Interaction Profile

The losartan-pregabalin interaction is pharmacodynamic, moderate in severity, and manageable with appropriate monitoring. It is not a contraindication. The shared risks are additive hypotension (driven by losartan's AT1 blockade combined with pregabalin's modest sympatholytic and vasodilatory properties) and additive CNS sedation. Patients with CKD face an additional indirect risk because reduced renal clearance raises pregabalin exposure, and losartan itself can lower GFR in vulnerable patients.

Check blood pressure sitting and standing within 2 weeks of starting or uptitrating pregabalin in any patient on losartan. Measure eGFR and adjust pregabalin dose if eGFR drops below 60 mL/min/1.73 m2. Start pregabalin at 75 mg/day in this setting rather than the standard 150 mg/day starting dose, and hold at that dose for at least 2 weeks before the first titration step.